+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
ContraFect Corporation - logo

ContraFect Corporation is a biotechnology company that develops therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

From
From
From
From
From
Osteomyelitis (Infectious Disease) - Drugs In Development, 2021 - Product Thumbnail Image

Osteomyelitis (Infectious Disease) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 55 Pages
  • Global
From
From
Staphylococcus aureus Bacteremia - Pipeline Insight, 2024 - Product Thumbnail Image

Staphylococcus aureus Bacteremia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Osteomyelitis - Pipeline Insight, 2024 - Product Thumbnail Image

Osteomyelitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Pseudomonal Infections - Pipeline Insight, 2024 - Product Thumbnail Image

Pseudomonal Infections - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 50 Pages
  • Global
From
From
Acinetobacter infections - Pipeline Insight, 2024 - Product Thumbnail Image

Acinetobacter infections - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Bacterial Therapeutics Beyond Antibiotics - Product Thumbnail Image

Bacterial Therapeutics Beyond Antibiotics

  • Report
  • June 2023
  • 130 Pages
  • Global
From
Loading Indicator